Alcon Universal Ltd.

Alcon, Inc.

Alcon Laboratories, Inc.

Alcon Manufacturing, Ltd.

Alcon Research, Ltd.

Novartis Ag

Alcon Laboraties, Inc.

Peter G Klimko

Mark R Hellberg

Paul W Zinke

Verney L Sallee

Gustav Graff

Raymond E Conrow

John E Bishop

Robert D Selliah

Daniel A Gamache

Robert J Collier, Jr

John M Yanni

John Russell Falck

David Benjamin Belanger

Clay Beauregard

Abbot F Clark

Thomas R Dean

Najam A Sharif

Iok-Hou Pang

David P Bingaman

Wan-Heng Wang

Loretta Graves McNatt

George E Barnes

Brenda W Griffin

Kenneth C Appell

Karen C David

David R Pierce

Martha E Gadd

Michael L Chandler

Tom R Dean

Louis Desantis Jr

The topical ophthalmic use of certain 2,4-diamino-substituted 1,3-triazines for preventing or alleviating ocular pain in patients is disclosed. Topical ocular pharmaceutical composition are also disclosed.

Topical ocular analgesic agents

The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.

Superoxide dismutase mimics for the treatment of ocular disorders and diseases

The topical use of 5,6,7-trihydroxyheptanoic acid and analogs alone or in combination with histamine antagonists and/or mast cell stabilizers is disclosed for the treatment of ocular allergy.

Method of treating ocular allergy

The use of SOD mimics particularly pentaazacycle Mncomplex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.

The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.

Method of treating dry eye disorders and uveitis

Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.

5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses

The present invention concerns a method for diagnosing or monitoring elevated intraocular pressure or glaucoma in a patient comprising providing a biological sample from the patient and measuring the expression level of a superoxide dismutase-2 (SOD-2) gene in the biological sample. The present invention also concerns methods for treating glaucoma or elevated intraocular pressure in a patient comprising administering to a patient an effective amount of an agent that modulates SOD-2 expression or SOD-2 activity.

Superoxide dismutase-2 expression for glaucoma diagnosis

The use of SOD mimics particularly pentaazacycle Mn(II) complex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.

The topical use of EgLN-3 inhibitors is disclosed for the treatment of dry eye.

Method of treating dry eye disorders

Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.

Method of treating glaucoma

Proteasome inhibitors are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

Use of proteasome inhibitors to treat dry eye disorders

11,12-Oxidoarachidonic acid derivatives and methods of their use for treating dry eye are disclosed.

11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders

Hydroxyeicosatetraenoic acid esters and methods of their use in treating dry eye disorders are disclosed.

Growing community of inventors

Fort Worth, TX, United States of America

Peter G Klimko